Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Blood (2022) 140 (5): 419–437.

https://doi.org/10.1182/blood.2021012057

Published: 2022

Journal Articles

A Novel Prognostic Index for Ocular Adnexal Lymphoma

Marshall W. Meeks, BS, Henry S. Park, MD MPH, James B. Yu, MD MHS, Kenneth B. Roberts, MD, Francine Foss, MD, Lynn D. Wilson, MD MPH

Blood (2016) 128 (22): 3597.

https://doi.org/10.1182/blood.V128.22.3597.3597

Published: 2016

Journal Articles

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Blood (2015) 126 (23): 341.

https://doi.org/10.1182/blood.V126.23.341.341

Published: 2015

Journal Articles

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

Madeleine Duvic, MD, Lauren Pinter-Brown, Francine Foss, MD, Lubomir Sokol, MD, PhD, Jeffrey Jorgensen, MD, PhD, Xiao Ni, MD, PhD, Pramoda Challagundla, MS, Meghali Goswami, BS, Karen Dwyer, Nehal Mohamed, PhD, Youn H Kim, MD

Blood (2012) 120 (21): 3697.

https://doi.org/10.1182/blood.V120.21.3697.3697

Published: 2012

Journal Articles

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

Steven M. Horwitz, Youn H. Kim, Francine Foss, Jasmine M. Zain, Patricia L. Myskowski, Mary Jo Lechowicz, David C. Fisher, Andrei R. Shustov, Nancy L. Bartlett, Maria L. Delioukina, Tony Koutsoukos, Michael E. Saunders, Owen A. O'Connor, Madeleine Duvic

Blood (2012) 119 (18): 4115–4122.

https://doi.org/10.1182/blood-2011-11-390211

Published: 2012

Journal Articles

Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma

Yingtai Chen, Tongzhang Zheng, Qing Lan, Francine Foss, Christopher Kim, Xuezhong Chen, Min Dai, Yumin Li, Theodore Holford, Brian Leaderer, Peter Boyle, Stephen J. Chanock, Nathaniel Rothman, Yawei Zhang

Blood (2011) 117 (2): 585–590.

https://doi.org/10.1182/blood-2010-07-295097

Published: 2011

Includes: Supplemental data

Journal Articles

Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy

Carole Berger, Kristin Hoffmann, Juan G. Vasquez, Shrikant Mane, Julia Lewis, Renata Filler, Aiping Lin, Hongyu Zhao, Tyler Durazzo, Abigail Baird, William Lin, Francine Foss, Inger Christensen, Michael Girardi, Robert Tigelaar, Richard Edelson

Blood (2010) 116 (23): 4838–4847.

https://doi.org/10.1182/blood-2009-11-256040

Published: 2010

Journal Articles

Complete Responses with Denileukin Diftitox in Cutaneous T-Cell Lymphoma Studies.

Francine Foss, MD, Madeleine Duvic, MD, Elise A. Olsen, MD, Anna Kozlovski, Pharm, D

Blood (2009) 114 (22): 3745.

https://doi.org/10.1182/blood.V114.22.3745.3745

Published: 2009

Journal Articles

Stem Cell Mobilization Using 5 Pm Dosing of Plerixafor.

Dennis L Cooper, MD, Julie Baker, APRN, Erin Medoff, APRN, Kathryn Pratt, RN, Ann Conkling-Walsh, RN, Edward L. Snyder, MD, Stuart Seropian, MD, Francine Foss, MD

Blood (2009) 114 (22): 4233.

https://doi.org/10.1182/blood.V114.22.4233.4233

Published: 2009

Journal Articles

A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Single Institution Experience

Frederick Lansigan, MD, Stuart Seropian, Dennis Cooper, Francine Foss

Blood (2008) 112 (11): 4392.

https://doi.org/10.1182/blood.V112.11.4392.4392

Published: 2008

Journal Articles

Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission?

Onder Alpdogan, MD, Raymond Lenox, APRN, Amy Barile, APRN, Francine Foss, MD, Warren Shlomchik, MD, Christy Reuben, APRN, Dennis Cooper, MD, Stuart Seropian, MD

Blood (2008) 112 (11): 4396.

https://doi.org/10.1182/blood.V112.11.4396.4396

Published: 2008

Journal Articles

Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL)

Onder Alpdogan, MD, Deborah Ornstein, MD, Tony Subtil, MD, Stuart Seropian, MD, Dennis L. Cooper, MD, Francine Foss, MD

Blood (2008) 112 (11): 3750.

https://doi.org/10.1182/blood.V112.11.3750.3750

Published: 2008

Journal Articles

Efficacy of Extracorporeal Photopheresis (ECP) Monotherapy in the Treatment of Cutaneous T Cell Lymphoma.

Larisa Geskin, MD, FAAD, Francine Foss, MD, Madeleine Duvic, MD, David Straus, MD, Steven Horwitz, MD, Jasmine Zain, MD, Timothy Kuzel, MD, Christiane Querfeld, MD, Kim Campbell, PhD, Robert Knobler, MD

Blood (2007) 110 (11): 2561.

https://doi.org/10.1182/blood.V110.11.2561.2561

Published: 2007

Journal Articles

Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study.

Madeleine Duvic, MD, Andres Forero-Torres, MD, Francine Foss, MD, Elise Olsen, MD, Youn Kim, MD

Blood (2007) 110 (11): 122.

https://doi.org/10.1182/blood.V110.11.122.122

Published: 2007

Journal Articles

Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.

Francine Foss, MD, Nelida Sjak-Shie, MD, PhD, Andre Goy, MD, Eric Jacobsen, MD, Ranjana Advani, MD, Mitchell Smith, MD, PhD, Rami Komrokji, MD, Kelly Pendergrass, MD, Vanessa Bolejack, MPH, Karen Watts, Mark Acosta, PharmD

Blood (2007) 110 (11): 3449.

https://doi.org/10.1182/blood.V110.11.3449.3449

Published: 2007

Journal Articles

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

Francine Foss, MD, Madeleine Duvic, MD, Larisa Geskin, MD, Joseph Anderson, MD, Pierluigi Porcu, MD, Raymond J. Hohl, MD,PhD, Maureen Cooper, MD, Jasmine M. Zain, MD, John Zic, MD, Patrica Hibberd, MD,PhD, Mark Acosta, PharmD

Blood (2006) 108 (11): 2712.

https://doi.org/10.1182/blood.V108.11.2712.2712

Published: 2006

Journal Articles

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Blood (2006) 108 (11): 2718.

https://doi.org/10.1182/blood.V108.11.2718.2718

Published: 2006

Journal Articles

A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.

Deborah A. Casale, MS, Nancy L. Bartlett, MD, David D. Hurd, MD, Francine Foss, MD, Barbara Pro, MD, Lubomir Sokol, MD, PhD, Ronald Lieberman, MD, Hammershaimb Luz, MD

Blood (2006) 108 (11): 2727.

https://doi.org/10.1182/blood.V108.11.2727.2727

Published: 2006

Journal Articles

FDG-PET Scans as a Staging Study for T-Cell Lymphomas: High Rates of Positivity Do Not Result in Frequent Changes in Stage.

Steven M. Horwitz, MD, Francine Foss, MD, Shari Goldfarb, MD, Ana Molina, MD, Paul A. Hamlin, MD, Owen A. O’Connor, MD, PHD, Michelle Cammarata, Craig H. Moskowitz, MD, Andrew D. Zelenetz, MD, PHD

Blood (2006) 108 (11): 2399.

https://doi.org/10.1182/blood.V108.11.2399.2399

Published: 2006

Journal Articles

Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.

Madeleine Duvic, MD, Andres Forero-Torres, MD, Francine Foss, MD, Elsie A. Olsen, MD, Youn Kim, MD

Blood (2006) 108 (11): 2467.

https://doi.org/10.1182/blood.V108.11.2467.2467

Published: 2006

NARROW

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

A Novel Prognostic Index for Ocular Adnexal Lymphoma

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma

Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy

Complete Responses with Denileukin Diftitox in Cutaneous T-Cell Lymphoma Studies.

Stem Cell Mobilization Using 5 Pm Dosing of Plerixafor.

A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Single Institution Experience

Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission?

Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL)

Efficacy of Extracorporeal Photopheresis (ECP) Monotherapy in the Treatment of Cutaneous T Cell Lymphoma.

Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study.

Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.

FDG-PET Scans as a Staging Study for T-Cell Lymphomas: High Rates of Positivity Do Not Result in Frequent Changes in Stage.

Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only